Peripheral blood stem cells: In vivo biology and therapeutic potential

摘要: Peripheral blood stem cells (PBSC) have been studied for their use after high-dose chemotherapy. The combination of a standard-dose chemotherapy [VIP: VP16 (etoposide), ifosfamide, cisplatin] in with hematopoietic growth factors was shown to provide effective anti-cancer activity as well enable sufficient cell mobilization clinical use. Different factor regimens [granulocyte-colony-stimulating (G-CSF), granulocyte-macrophage (GM)-CSF, interleukin (IL)-3/GM-CSF] resulted differential induction high levels circulating PBSC VIP chemotherapy, the sequential IL-3 and GM-CSF inducing maximal numbers CD34+ clonogenic progenitors. Our studies revealed correlation between prior treatment recruitment: highest were mobilized untreated patients whereas harvest considerably impeded heavily pretreated patients. Phase I/II trials demonstrated that transplantation collected plus safe, engraftment rapid sustained. However, carried risk concomitant tumor recruitment detectable therapy 21% without cells. Positive selection by immunoadsorption leads an approximately three-log depletion contaminating therefore investigated regard feasibility capability source transplantation. Twenty-one advanced malignancies received autologous Hematological recovery recorded unseparated preparations, indicating can be safely used transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)